 |
|
National Trends in Antiobesity Medication Use
Randall S. Stafford, MD, PhD;
David C. Radley, BA
Arch Intern Med. 2003;163:1046-1050.
Background The use of medications to treat obesity remains controversial. Our goal was to assess national trends in antiobesity medication use with a focus on patterns surrounding the 1997 removal of antiobesity drugs from the market.
Methods Using a serial cross-sectional study design, we analyzed a nationally representative sample of US office-based physician visits from 1991 to 2002. Data come from the IMS HEALTH National Disease and Therapeutic Index. These data include a sample of 13 452 patient visits for which a diagnosis of clinical obesity was made, with annual visits ranging from 666 in 1994 to 1854 in 1996. The unit of analysis is the patient visit, while the primary outcome measures are the annual and quarterly number of antiobesity drug mentions for clinically obese patients.
Results At its peak in the second quarter of 1997, 2.5 million Americans were taking antiobesity medications, a 4-fold increase over the prior 2 years. Although antiobesity medication use diminished following the market exit of fenfluramine hydrochloride and dexfenfluramine hydrochloride, current levels of use remain above those in the early 1990s. Phentermine has consistently been the most common antiobesity medication. In 2002, an annualized 1.2 million mentions of phentermine use were noted (31% of drug-treated obese patients). Newly released medications, orlistat (0.6 million) and sibutramine hydrochloride (0.4 million), were used less often. Most antiobesity medication use occurs in patients without other reported medical conditions.
Conclusions Use of antiobesity medications increased rapidly with public and professional interest in fenfluramine-phentermine (fen-phen) combination therapy. Despite reports of adverse outcomes associated with fenfluramine agents (fen-phen and dexfenfluramine), the use of these medication therapies did not diminish until soon before their removal from the market in 1997.
From Stanford Center for Research in Disease Prevention, Palo Alto, Calif (Dr Stafford), and Yale University School of Epidemiology and Public Health, New Haven, Conn (Mr Radley). The authors have no relevant financial interest in this article.
RELATED LETTER
Physicians' Personal Intake and Prescription of Weight Loss Products: Are We Practicing What We Preach?
John La Puma, Philippe Szapary, and Kevin C. Maki
Arch Intern Med. 2004;164(7):806-807.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks
Gadde and Allison
Circulation 2006;114:974-984.
FULL TEXT
Use And Costs Of Bariatric Surgery And Prescription Weight-Loss Medications
Encinosa et al.
Health Aff (Millwood) 2005;24:1039-1046.
ABSTRACT
| FULL TEXT
Clinical Implications of Obesity With Specific Focus on Cardiovascular Disease: A Statement for Professionals From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation
Klein et al.
Circulation 2004;110:2952-2967.
ABSTRACT
| FULL TEXT
Promotion and Prescribing of Hormone Therapy After Report of Harm by the Women's Health Initiative
Majumdar et al.
JAMA 2004;292:1983-1988.
ABSTRACT
| FULL TEXT
Physicians' Personal Intake and Prescription of Weight Loss Products: Are We Practicing What We Preach?
La Puma et al.
Arch Intern Med 2004;164:806-807.
FULL TEXT
Treating Obesity: New Directions
JWatch Psychiatry 2003;2003:2-2.
FULL TEXT
|
